Refine
Has Fulltext
- yes (82)
Is part of the Bibliography
- yes (82)
Year of publication
Document Type
- Journal article (67)
- Doctoral Thesis (14)
- Report (1)
Language
- English (82) (remove)
Keywords
- platelets (11)
- platelet (10)
- ischemic stroke (7)
- LASP1 (6)
- Thrombozyt (5)
- atherosclerosis (5)
- megakaryocytes (5)
- thrombo-inflammation (5)
- CXCR4 (4)
- glycoprotein VI (4)
- platelet activation (4)
- thrombosis (4)
- Cytoskeleton (3)
- Megakaryozyt (3)
- cytoskeleton (3)
- cytotoxic T cells (3)
- inflammation (3)
- mouse (3)
- platelet aggregation (3)
- thrombin (3)
- thrombopoiesis (3)
- AAA (2)
- CML (2)
- COVID-19 (2)
- Caenorhabditis elegans (2)
- Knochenmark (2)
- Phagozytose (2)
- Zellskelett (2)
- Zelltod (2)
- actin cytoskeleton (2)
- aortic arch (2)
- blood (2)
- bone marrow (2)
- breast cancer (2)
- collagens (2)
- epigenetics (2)
- glycoprotein receptor Ib (2)
- hematology (2)
- ischemic penumbra (2)
- matrix metalloproteinases (2)
- mice (2)
- middle cerebral artery occlusion (2)
- mouse models (2)
- platelet receptors (2)
- pulse wave velocity (2)
- signaling (2)
- stem cells (2)
- transcriptional regulation (2)
- translational research (2)
- wall shear stress (2)
- 3D image analysis (1)
- 4D flow (1)
- 4D flow MRI (1)
- 7-Dehydrocholesterol (1)
- A20 (1)
- ADAM10 (1)
- AKT (1)
- AKT1 (1)
- AP-1 (1)
- AP1 (1)
- Abszision (1)
- Actin (1)
- Actin-bindende Proteine (1)
- Adhesion and degranulation promoting adapter protein (1)
- Akt (1)
- Arteriosklerose (1)
- Artery Models (1)
- Atherosclerosis (1)
- Autophagie (1)
- B cell (1)
- B cell maturation (1)
- B cell receptor (1)
- BCR‐ABL (1)
- Batf3 (1)
- Bericht (1)
- Biofabrication (1)
- CD147 (1)
- CD2AP (1)
- CD8\(^+\) T cells (1)
- CMR (1)
- Canis lupus familiaris (1)
- Cdc42 (1)
- Cholesterin (1)
- Cholesterol (1)
- Collaborative Research Center (1)
- Cyclophilin A (1)
- DHCR7 (1)
- Differential RNA-sequencing (1)
- E2 conjugating enzyme (1)
- E3 ligating enzyme (1)
- EMMPRIN (1)
- ERK map kinease (1)
- ERK1/2 (1)
- Experimental Biomedicine (1)
- Extracellular matrix proteins (1)
- Extrazelluläre Matrix (1)
- Ferroptose (1)
- Ferroptosis (1)
- GABAA receptors (1)
- GABP (1)
- GPR54 (1)
- GPVI (1)
- GSK-3β (1)
- Ganzkörperbestrahlung (1)
- Helicobacter pylori (1)
- Hemodynamics (1)
- Herzinfarkt (1)
- Histologie (1)
- Hämodynamik (1)
- IgD (1)
- IgM (1)
- JAQ1 (1)
- KAT/HAT (1)
- KISS1 receptor (1)
- KISS1-54 (1)
- Knochenmarktransplantation (1)
- LASP2 (1)
- LC3-associated phagocytosis (1)
- LC3-assoziierte Phagozytose (1)
- MGL (1)
- MRI (1)
- Macrophages (1)
- Makrophage (1)
- Mast cells (1)
- Megakaryocyte (1)
- Megakaryocytes (1)
- Myocardial infarction (1)
- Neutrophils (1)
- Optogenetik (1)
- Orai2 (1)
- PET (1)
- PWV (1)
- Platelet (1)
- Polkörper (1)
- RKIP (1)
- RhoA (1)
- RhoF (1)
- SARS-CoV-2 (1)
- Septine (1)
- Snail1 stability (1)
- Sonderforschungsbereich Transregio 240 (1)
- Strumpellin (1)
- Syk (1)
- T-cell epitope (1)
- T-cells (1)
- Tet‐inducible system (1)
- Thrombopoiesis (1)
- Thrombozytopenie (1)
- Tissue Engineering (1)
- TspanC8 (1)
- WASH complex (1)
- WSS (1)
- ZF1 degradation assay (1)
- ZIP (1)
- Zellteilung (1)
- [\(^{68}\)]KISS1-54 (1)
- acetylation (1)
- acetyltransferases (1)
- actin-binding proteins (1)
- actins (1)
- acute Respiratory Distress Syndrome (1)
- adaptor protein Swiprosin-1/EFhd2 (1)
- adipose tissue (1)
- algorithm (1)
- alpha-IIb beta-3 (1)
- angiotensin (1)
- animal models (1)
- arterial elasticity (1)
- arterial thrombus formation (1)
- basic (laboratory) research / science (1)
- bioenergetics (1)
- bioinformatics (1)
- bleding disorders other than hemophilia (1)
- bleeding (1)
- blood coagulation (1)
- blood flow (1)
- blood platelets (1)
- body weight (1)
- brain (1)
- c-Fos (1)
- cag pathogenicity island (1)
- campylobacter jejuni infection (1)
- cancer (1)
- cardiovascular MRI (1)
- cardiovascular disease (1)
- carotid arteries (1)
- cascade (1)
- cerebellum (1)
- cerebrovascular disorders (1)
- checkpoint inhibitors (1)
- coagulation (1)
- coagulation and hemostasis (1)
- coagulation system (1)
- coatings (1)
- coffin-lowry-syndrome (1)
- collagen (1)
- complex (1)
- controllability (1)
- cyclase-associated protein (1)
- cyclase-associated protein 2 (1)
- cytoskeletal proteins (1)
- deficiency (1)
- dendritic cells (1)
- dendritic growth (1)
- dentate gyrus (1)
- disaggregation (1)
- disease (1)
- dog (1)
- drug repurposing (1)
- early diagnosis (1)
- ectopic release (1)
- embryos (1)
- en bloc transfer (1)
- endosomal trafficking (1)
- endothelial cell (1)
- endothelial cells (1)
- enzyme regulation (1)
- epithelial cells (1)
- epitope prediction (1)
- evolution (1)
- extracellular matrix (1)
- factor XII (1)
- fibrin (1)
- filopodia (1)
- flow (1)
- flow dynamics (1)
- fluorescence microscopy (1)
- fostamatinib (1)
- genes (1)
- genetic modification (1)
- gephyrin (1)
- glaucoma (1)
- glycine receptors (1)
- glycoprotein Ib (1)
- glycoprotein Ibα (1)
- glycoprotein receptor Ibα (1)
- graft survival (1)
- granule cells (1)
- guidelines (1)
- haemostasis (1)
- heart (1)
- hemorrhage (1)
- hemostasis and thrombosis (1)
- hemostasis, (1)
- hepatology (1)
- hippocampus (1)
- histologic diversity (1)
- histology (1)
- histone acetylation (1)
- homeostasisIon channels (1)
- human (1)
- human hematopoiesis (1)
- human tumor cell lines (1)
- hypothalamus (1)
- iPS cells (1)
- imaging the immune system (1)
- imiquimod (1)
- immune-informatics (1)
- immunoglobulin repertoire (1)
- immunoglobulin superfamily (1)
- immunotherapy (1)
- impedance aggregometry; WHOLE-BLOOD THROMBOELASTOMETRY; DEFINITION; DISEASE (1)
- in vitro and in vivo thrombus formation (1)
- infection (1)
- influenza (1)
- inherited macrothrombocytopenia (1)
- inhibitory post-synaptic specialization (1)
- insulin (1)
- insulin resistance (1)
- integrin α2 (1)
- integrins (1)
- interaction (1)
- interactome (1)
- interspecies comparison (1)
- intracranial bleeding (1)
- islet transplantation (1)
- kisspeptin (1)
- laboratory animals (1)
- large animal models (1)
- leukemia (1)
- light sheet fluorescence microscopy (1)
- lncRNAs (1)
- long-term potentation (1)
- lung cancer (1)
- lung injury (1)
- lymphocyte differentiation (1)
- magnetic resonance imaging (1)
- mapping (1)
- megakaryocyte (1)
- metalloproteinase (1)
- metals (1)
- miRNA expression (1)
- miRNAs (1)
- microfluidics (1)
- microscopy (1)
- midbody remnant (1)
- molecular biology (1)
- monocyte-platelet aggregates (1)
- moonlighting protein (1)
- mutation (1)
- myeloablation (1)
- nephrocyte (1)
- network (1)
- neurite outgrowth (1)
- neurology (1)
- neuronal dendrites (1)
- neuronal differentiation (1)
- neurons (1)
- neurotrophic factor (1)
- neurotrophic factors (1)
- neutrophil (1)
- nilotinib (1)
- non-invasive biomarkers (1)
- nuclear role (1)
- nucleus (1)
- occlusion (1)
- optical clearing (1)
- optogenetics (1)
- organoid (1)
- pathway analysis (1)
- phagosome maturation (1)
- phosphatidic acid (1)
- phospholipase D (1)
- phosphorylation (1)
- pig (1)
- pigmentation (1)
- plaque (1)
- plaque characteristics (1)
- platelet biogenesis (1)
- platelet degranulation (1)
- platelet disorders (1)
- platelet inhibition (1)
- platelet-neutrophil complexes (PNCs) (1)
- pneumonia (1)
- point of care testing (1)
- polymers (1)
- popliteal aneurysm (1)
- positive selection (1)
- positron emission tomography (1)
- precursor cells (1)
- proplatelets (1)
- protein RSK2 (1)
- proteome (1)
- psoriasis (1)
- quantification (1)
- radial (1)
- recombinant tissue-type plasminogen activator (1)
- regulatory circuit downstream (1)
- research infrastructure (1)
- retroviral vectors (1)
- second messenger (1)
- self-navigation (1)
- sequential addition (1)
- serotonin (1)
- shedding (1)
- signaling network (1)
- single cell RNA sequencing (1)
- slit membrane (1)
- spatiotemporal thrombus (1)
- stent implantation (1)
- stroke (1)
- structure (1)
- tMCAO (1)
- tetraspanin (1)
- therapy (1)
- thrombocyte (1)
- thrombocytopenia (1)
- thromboelastometry (1)
- thrombus (1)
- transcriptome (1)
- transendothelial migration (1)
- transient middle cerebral artery (1)
- transient middle cerebral artery occlusion (1)
- tumor microenvironment (1)
- tyrosine kinase (1)
- ubiquitin (1)
- ultrahigh-field MRI (1)
- vascular structure (1)
- viral infection (1)
- zinc (1)
Institute
- Institut für Experimentelle Biomedizin (82) (remove)
Sonstige beteiligte Institutionen
T cell exhaustion is a hallmark of cancer and persistent infections, marked by inhibitory receptor upregulation, diminished cytokine secretion, and impaired cytolytic activity. Terminally exhausted T cells are steadily replenished by a precursor population (Tpex), but the metabolic principles governing Tpex maintenance and the regulatory circuits that control their exhaustion remain incompletely understood. Using a combination of gene-deficient mice, single-cell transcriptomics, and metabolomic analyses, we show that mitochondrial insufficiency is a cell-intrinsic trigger that initiates the functional exhaustion of T cells. At the molecular level, we find that mitochondrial dysfunction causes redox stress, which inhibits the proteasomal degradation of hypoxia-inducible factor 1α (HIF-1α) and promotes the transcriptional and metabolic reprogramming of Tpex cells into terminally exhausted T cells. Our findings also bear clinical significance, as metabolic engineering of chimeric antigen receptor (CAR) T cells is a promising strategy to enhance the stemness and functionality of Tpex cells for cancer immunotherapy.
Ultra-high field cardiac MRI in large animals and humans for translational cardiovascular research
(2023)
A key step in translational cardiovascular research is the use of large animal models to better understand normal and abnormal physiology, to test drugs or interventions, or to perform studies which would be considered unethical in human subjects. Ultrahigh field magnetic resonance imaging (UHF-MRI) at 7 T field strength is becoming increasingly available for imaging of the heart and, when compared to clinically established field strengths, promises better image quality and image information content, more precise functional analysis, potentially new image contrasts, and as all in-vivo imaging techniques, a reduction of the number of animals per study because of the possibility to scan every animal repeatedly. We present here a solution to the dual use problem of whole-body UHF-MRI systems, which are typically installed in clinical environments, to both UHF-MRI in large animals and humans. Moreover, we provide evidence that in such a research infrastructure UHF-MRI, and ideally combined with a standard small-bore UHF-MRI system, can contribute to a variety of spatial scales in translational cardiovascular research: from cardiac organoids, Zebra fish and rodent hearts to large animal models such as pigs and humans. We present pilot data from serial CINE, late gadolinium enhancement, and susceptibility weighted UHF-MRI in a myocardial infarction model over eight weeks. In 14 pigs which were delivered from a breeding facility in a national SARS-CoV-2 hotspot, we found no infection in the incoming pigs. Human scanning using CINE and phase contrast flow measurements provided good image quality of the left and right ventricle. Agreement of functional analysis between CINE and phase contrast MRI was excellent. MRI in arrested hearts or excised vascular tissue for MRI-based histologic imaging, structural imaging of myofiber and vascular smooth muscle cell architecture using high-resolution diffusion tensor imaging, and UHF-MRI for monitoring free radicals as a surrogate for MRI of reactive oxygen species in studies of oxidative stress are demonstrated. We conclude that UHF-MRI has the potential to become an important precision imaging modality in translational cardiovascular research.
Current therapeutic strategies efficiently improve survival in patients after myocardial infarction (MI). Nevertheless, long-term consequences such as heart failure development, are still one of the leading causes of death worldwide. Inflammation is critically involved in the cardiac healing process after MI and has a dual role, contributing to both tissue healing and tissue damage. In the last decade, a lot of attention was given to targeting inflammation as a potential therapeutic approach in MI, but the poor understanding of inflammatory cell heterogeneity and function is a limit to the development of immune modulatory strategies. The recent development of tools to profile immune cells with high resolution has provided a unique opportunity to better understand immune cell heterogeneity and dynamics in the ischemic heart.
In this thesis, we employed single-cell RNA-sequencing combined with detection of epitopes by sequencing (CITE-seq) to refine our understanding of neutrophils and monocytes/macrophages heterogeneity and dynamic after experimental myocardial infarction.
Neutrophils rapidly invade the infarcted heart shortly after ischemic damage and have previously been proposed to display time-dependent functional heterogeneity. At the single-cell level, we observed dynamic transcriptional heterogeneity in neutrophil populations during the acute post-MI phase and defined previously unknown cardiac neutrophil states. In particular, we identified a locally acquired SiglecFhi neutrophil state that displayed higher ROS production and phagocytic ability compared to newly recruited neutrophils, suggesting the acquisition of specific function in the infarcted heart. These findings highlight the importance of the tissue microenvironment in shaping neutrophil response.
From the macrophage perspective, we characterized MI-associated monocyte-derived macrophage subsets, two with a pro-inflammatory gene signature (MHCIIhiIl1βhi) and three Trem2hi macrophage populations with a lipid associated macrophage (LAM) signature, also expressing pro-fibrotic and tissue repair genes. Combined analysis of blood monocytes and cardiac monocyte/macrophages indicated that the Trem2hi LAM signature is acquired in the infarcted heart.
We furthermore characterized the role of TREM2, a surface protein expressed mainly in macrophages and involved in macrophage survival and function, in the post-MI macrophage response and cardiac repair. Using TREM2 deficient mice, we demonstrate that acquisition of the LAM signature in cardiac macrophages after MI is partially dependent on TREM2. While their cardiac function was not affected, TREM2 deficient mice showed reduced collagen deposition in the heart after MI. Thus, our data in Trem2-deficient mice highlight the role of TREM2 in promoting a macrophage pro-fibrotic phenotype, in line with the pro-fibrotic/tissue repair gene signature of the Trem2hi LAM-signature genes.
Overall, our data provide a high-resolution characterization of neutrophils and macrophage heterogeneity and dynamics in the ischemic heart and can be used as a valuable resource to investigate how these cells modulate the healing processes after MI. Furthermore, our work identified TREM2 as a regulator of macrophage phenotype in the infarcted heart
Kisspeptins (KPs, KISS1) and their receptor (KISS1R) play a pivotal role as metastasis suppressor for many cancers. Low or lost KP expression is associated with higher tumor grade, increased metastatic potential, and poor prognosis. Therefore, KP expression has prognostic relevance and correlates with invasiveness in cancers. Furthermore, KISS1R represents a very promising target for molecular imaging and therapy for KISS1R-expressing tumors. The goal of this study was to evaluate the developed KISS1-54 derivative, [\(^{68}\)Ga]KISS1-54, as a PET-imaging probe for KISS1R-expressing tumors. The NODAGA-KISS1-54 peptide was labeled by Gallium-68, and the stability of the resulting [\(^{68}\)Ga]KISS1-54 evaluated in injection solution and human serum, followed by an examination in different KISS1R-expressing tumor cell lines, including HepG2, HeLa, MDA-MB-231, MCF7, LNCap, SK-BR-3, and HCT116. Finally, [\(^{68}\)Ga]KISS1-54 was tested in LNCap- and MDA-MB-231-bearing mice, using µ-PET, assessing its potential as an imaging probe for PET. [\(^{68}\)Ga]KISS1-54 was obtained in a 77 ± 7% radiochemical yield and at a >99% purity. The [\(^{68}\)Ga]KISS1-54 cell uptake amounted to 0.6–4.4% per 100,000 cells. Moreover, the accumulation of [\(^{68}\)Ga]KISS1-54 was effectively inhibited by nonradioactive KISS1-54. In [\(^{68}\)Ga]KISS1-54-PET, KISS1R-positive LNCap-tumors were clearly visualized as compared to MDA-MB-231-tumor implant with predominantly intracellular KISS1R expression. Our first results suggest that [\(^{68}\)Ga]KISS1-54 is a promising candidate for a radiotracer for targeting KISS1R-expressing tumors via PET.
Cyclophilin a is not acetylated at lysine-82 and lysine-125 in resting and stimulated platelets
(2022)
Cyclophilin A (CyPA) is widely expressed by all prokaryotic and eukaryotic cells. Upon activation, CyPA can be released into the extracellular space to engage in a variety of functions, such as interaction with the CD147 receptor, that contribute to the pathogenesis of cardiovascular diseases. CyPA was recently found to undergo acetylation at K82 and K125, two lysine residues conserved in most species, and these modifications are required for secretion of CyPA in response to cell activation in vascular smooth muscle cells. Herein we addressed whether acetylation at these sites is also required for the release of CyPA from platelets based on the potential for local delivery of CyPA that may exacerbate cardiovascular disease events. Western blot analyses confirmed the presence of CyPA in human and mouse platelets. Thrombin stimulation resulted in CyPA release from platelets; however, no acetylation was observed—neither in cell lysates nor in supernatants of both untreated and activated platelets, nor after immunoprecipitation of CyPA from platelets. Shotgun proteomics detected two CyPA peptide precursors in the recombinant protein, acetylated at K28, but again, no acetylation was found in CyPA derived from resting or stimulated platelets. Our findings suggest that acetylation of CyPA is not a major protein modification in platelets and that CyPA acetylation is not required for its secretion from platelets.
During ischemic stroke, infarct growth before recanalization diminishes functional outcome. Hence, adjunct treatment options to protect the ischemic penumbra before recanalization are eagerly awaited. In experimental stroke targeting two different pathways conferred protection from penumbral tissue loss: (1) enhancement of hypoxic tolerance of neurons by deletion of the calcium channel subunit Orai2 and (2) blocking of detrimental lymphocyte–platelet responses. However, until now, no preclinical stroke study has assessed the potential of combining neuroprotective with anti-thrombo-inflammatory interventions to augment therapeutic effects. We induced focal cerebral ischemia in Orai2-deficient (Orai2\(^{-/-}\)) mice by middle cerebral artery occlusion (MCAO). Animals were treated with anti-glycoprotein Ib alpha (GPIbα) Fab fragments (p0p/B Fab) blocking GPIbα–von Willebrand factor (vWF) interactions. Rat immunoglobulin G (IgG) Fab was used as the control treatment. The extent of infarct growth before recanalization was assessed at 4 h after MCAO. Moreover, infarct volumes were determined 6 h after recanalization (occlusion time: 4 h). Orai2 deficiency significantly halted cerebral infarct progression under occlusion. Inhibition of platelet GPIbα further reduced primary infarct growth in Orai2\(^{-/-}\) mice. During ischemia–reperfusion, upon recanalization, mice were likewise protected. All in all, we show that neuroprotection in Orai2\(^{-/-}\) mice can be augmented by targeting thrombo-inflammation. This supports the clinical development of combined neuroprotective/anti-platelet strategies in hyper-acute stroke.
Targeting of a conserved epitope in mouse and human GPVI differently affects receptor function
(2022)
Glycoprotein (GP) VI is the major platelet collagen receptor and a promising anti-thrombotic target. This was first demonstrated in mice using the rat monoclonal antibody JAQ1, which completely blocks the Collagen-Related Peptide (CRP)-binding site on mouse GPVI and efficiently inhibits mouse platelet adhesion, activation and aggregation on collagen. Here, we show for the first time that JAQ1 cross-reacts with human GPVI (huGPVI), but not with GPVI in other tested species, including rat, rabbit, guinea pig, swine, and dog. We further demonstrate that JAQ1 differently modulates mouse and human GPVI function. Similar to its effects on mouse GPVI (mGPVI), JAQ1 inhibits CRP-induced activation in human platelets, whereas, in stark contrast to mouse GPVI, it does not inhibit the adhesion, activation or aggregate formation of human platelets on collagen, but causes instead an increased response. This effect was also seen with platelets from newly generated human GPVI knockin mice (hGP6\(^{tg/tg\)). These results indicate that the binding of JAQ1 to a structurally conserved epitope in GPVI differently affects its function in human and mouse platelets.
LIM and SH3 protein 1 was originally identified as a structural cytoskeletal protein with scaffolding function. However, recent data suggest additional roles in cell signaling and gene expression, especially in tumor cells. These novel functions are primarily regulated by the site-specific phosphorylation of LASP1. This review will focus on specific phosphorylation-dependent interaction between LASP1 and cellular proteins that orchestrate primary tumor progression and metastasis. More specifically, we will describe the role of LASP1 in chemokine receptor, and PI3K/AKT signaling. We outline the nuclear role for LASP1 in terms of epigenetics and transcriptional regulation and modulation of oncogenic mRNA translation. Finally, newly identified roles for the cytoskeletal function of LASP1 next to its known canonical F-actin binding properties are included.
Platelets play an essential role in haemostasis. Through granule secretion of second wave mediators and aggregation, they secure vascular integrity. Due to incorrect activation, platelet aggregation and subsequent thrombus formation can cause blood vessel occlusion, leading to ischemia. Patients with defects in platelet production have a low platelet count (thrombocytopenia), which can cause an increased bleeding risk. In vitro platelet generation is still in its development phase. So far, no convincing results have been obtained. For this reason, the health care system still depends on blood donors. Platelets are produced by bone marrow megakaryocytes (MKs), which extend long cytoplasmic protrusions, designated proplatelets, into sinusoidal blood vessels. Due to shear forces, platelets are then released into the bloodstream. The molecular mechanisms underlying platelet production are still not fully understood. However, a more detailed insight of this biological process is necessary to improve the in vitro generation of platelets and to optimise treatment regimens of patients.
Optogenetics is defined as “light-modulation of cellular activity or of animal behaviour by gene transfer of photo-sensitive proteins”. Optogenetics has had a big impact on neuroscience over the last decade. The use of channelrhodopsin 2 (ChR2), a light-sensitive cation channel, made it possible to stimulate neurons precisely and minimally invasive for the first time. Recent developments in the field of optogenetics intend to address a broader scope of cellular and molecular biology.
The aim of this thesis is to establish optogenetics in the field of MK research in order to precisely control and manipulate MK differentiation. An existing “optogenetic toolbox“ was used, which made it possible to light-modulate the cellular concentration of specific signalling molecules and ion conductance in MKs. Expression of the bacterial photoactivated adenylyl cyclase (bPAC) resulted in a significant increase in cAMP concentration after 5 minutes of illumination. Similarly, intracellular cGMP concentrations in MKs expressing photoactivated guanylyl cyclase (BeCyclop) were elevated. Furthermore, proplatelet formation of MKs expressing the light-sensitive ion channels ChR2 and anion channelrhodopsin (ACR) was altered in a light-dependent manner. These results show that MK physiology can be modified by optogenetic approaches. This might help shed new light on the underlying mechanisms of thrombopoiesis.
Understanding the pathways involved in the formation and stability of the core and shell regions of a platelet-rich arterial thrombus may result in new ways to treat arterial thrombosis. The distinguishing feature between these two regions is the absence of fibrin in the shell which indicates that in vitro flow-based assays over thrombogenic surfaces, in the absence of coagulation, can be used to resemble this region. In this study, we have investigated the contribution of Syk tyrosine kinase in the stability of platelet aggregates (or thrombi) formed on collagen or atherosclerotic plaque homogenate at arterial shear (1000 s\(^{−1}\)). We show that post-perfusion of the Syk inhibitor PRT-060318 over preformed thrombi on both surfaces enhances thrombus breakdown and platelet detachment. The resulting loss of thrombus stability led to a reduction in thrombus contractile score which could be detected as early as 3 min after perfusion of the Syk inhibitor. A similar loss of thrombus stability was observed with ticagrelor and indomethacin, inhibitors of platelet adenosine diphosphate (ADP) receptor and thromboxane A\(_2\) (TxA\(_2\)), respectively, and in the presence of the Src inhibitor, dasatinib. In contrast, the Btk inhibitor, ibrutinib, causes only a minor decrease in thrombus contractile score. Weak thrombus breakdown is also seen with the blocking GPVI nanobody, Nb21, which indicates, at best, a minor contribution of collagen to the stability of the platelet aggregate. These results show that Syk regulates thrombus stability in the absence of fibrin in human platelets under flow and provide evidence that this involves pathways additional to activation of GPVI by collagen.